Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2018-04-06 Declaration of Voting R…
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
180405 OutstandingShares_April2018_NL_FINAL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "PERSBERICHT GEREGLEMENTEERDE INFORMATIE" (REGULATED INFORMATION PRESS RELEASE) and its primary content is the "OPENBAARMAKING VAN UITSTAANDE STEMRECHTVERLENENDE EFFECTEN" (DISCLOSURE OF OUTSTANDING VOTING RIGHTS SECURITIES). It details the issuance of new shares following option exercises and updates the total outstanding share capital and voting rights, referencing Belgian law regarding disclosure of significant shareholdings (Belgische Wet van 2 mei 2007). This type of announcement, which reports on changes in the total number of shares and voting rights, directly relates to capital structure changes and major shareholding notifications. Since the document explicitly announces the change in the total number of shares and potential shares issuable under various plans, it fits best under Capital/Financing Update (CAP) or Major Shareholding Notification (MRQ). Given the focus on the total number of shares and the mechanism for future issuance (options/warrants), it is fundamentally a disclosure about the company's capital structure post-issuance. However, the core action is the disclosure of the new total share count, which is a key component of capital structure updates. It is not a general earnings release (ER), an interim report (IR), or a proxy statement (PSI). It is a specific regulatory disclosure about the share count. The closest fit among the provided options that covers changes in capital structure and share counts is 'Capital/Financing Update' (CAP), although 'Major Shareholding Notification' (MRQ) is also relevant if the change crossed a threshold, but the document focuses on the total count itself. Given the explicit mention of new shares issued and the resulting total capital structure, CAP is the most appropriate classification for this specific type of capital disclosure.
2018-04-06 Dutch
BC_AR_2017_ENG-low-res-signatures.pdf
Annual Report Classification · 100% confidence The document is titled 'Annual report 2017' and contains comprehensive sections including a message from the Chairman and CEO, corporate governance, remuneration reports, consolidated financial statements, and an auditor's report. It covers the full fiscal year 2017 and provides detailed financial and operational performance data, fitting the definition of an Annual Report (10-K). FY 2017
2018-04-05 English
180404 PR Annual report 2017 publication NL FINALdocx.pdf
Report Publication Announcement Classification · 99% confidence The document is titled "Biocartis kondigt publicatie van zijn 2017 jaarverslag aan" (Biocartis announces publication of its 2017 annual report). It is a short press release (4045 characters) explicitly stating that the 2017 annual report is now available for download. According to Rule 2 (The "MENU VS MEAL" Rule), a short document announcing the publication of a full report should be classified as a Report Publication Announcement (RPA), rather than the full report itself (10-K). The text confirms the publication of the 'jaarverslag' (annual report) for the year ended December 31, 2017, but does not contain the full content of that report.
2018-04-05 French
BC_AR_2017_NLD-low-res-Signatures.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2017' (Annual Report 2017) for Biocartis Group. It contains a comprehensive structure including a message from the CEO/Chairman, corporate governance, remuneration reports, consolidated financial statements, and the auditor's report. It is clearly the full annual report rather than an announcement or a summary, as it provides detailed financial data and business analysis for the fiscal year 2017. FY 2017
2018-04-05 Dutch
EIB Financing Facility - eng
Capital/Financing Update Classification · 98% confidence The document is explicitly labeled as a "PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION" dated March 1, 2018. The content details the company (Biocartis) obtaining a significant debt financing facility (up to EUR 24m) from the European Investment Bank, supported by an EU program. This announcement concerns a major financial/capital event—securing debt financing. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific, material financing transaction.
2018-03-01 English
EIB Financing Facility - nl
Capital/Financing Update Classification · 99% confidence The document is a press release (indicated by 'PERSBERICHT GEREGLEMENTEERDE INFORMATIE') announcing that Biocartis has secured a debt financing facility of up to EUR 24 million from the European Investment Bank (EIB), supported by the EU's Horizon 2020 program, specifically for infectious disease projects. This announcement details the terms of the financing, quotes key stakeholders (EU Commissioner, EIB VP, Biocartis CEO), and describes the intended use of the funds (IDYLLA™ platform expansion). This clearly falls under the category of updates regarding company fundraising, financing activities, or capital structure changes, which corresponds to the 'Capital/Financing Update' definition. Code: CAP.
2018-03-01 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.